Environ impact banner image

We are committed to environmental stewardship across the product lifecycle, from discovery and development, through to manufacturing, marketing, use and ultimately disposal. We are also committed to minimising the environmental impact of our operations by reducing the carbon footprint and natural resource demands of our own and our suppliers’ business activities.

Environment
 is an area in which we believe we have both
 the capability and the responsibility to implement activities that accelerate our business strategy, while delivering wider benefits to society and the environment.

By the end of 2015 we aim to: 

  • Reduce our operational greenhouse gas footprint (excluding emissions from patient use of our inhaler therapies) by 20 percent from our 2010 levels
  • Reduce our hazardous and non-hazardous waste by 15 percent from our 2010 levels
  • Reduce our water use by 25 percent from our 2010 levels.
     

What we're doing

Setting future targets

In 2015, we will be setting new targets for the future. We want to take on a fair share of responsibility, which is why our thinking on future targets will be based around the World Resources Institute, World Wildlife Fund and Carbon Disclosure Project joint initiative on science-based target setting announced in their report ‘Mind the Science: Mind the Gap’. The initiative aims to develop a new, sector-specific methodology that helps companies set science-based emission reduction targets, based not on existing carbon reduction projects in its own pipeline, but on the levels that will avoid the worst impacts of climate change.

Gaining external perspectives

In 2014, we secured the support of an Environmental Sustainability Advisory Board. Made up of a group of four leading experts from around the world, their role is to challenge and advise us on all aspects of our environment strategy. The members of the Advisory Board are:

  • Pankaj Bhatia, World Resources Institute, Washington
  • Prof Jorgen Randers, Climate Strategy, BI Norwegian Business School
  • Prof Koen Steemers, Head of Sustainable Design, Head of Department Architecture, University of Cambridge
  • Polly Courtice, Director of the University of Cambridge Institute for Sustainability Leadership.

At the first meeting in October 2014, the Advisory Board provided feedback on proposed future environmental targets for beyond 2015 and challenged us to incorporate the concept of fair share as we develop these further and roll them out across the business. The Board will meet twice a year.
 

Reducing our carbon footprint

In 2014, we were admitted into the Carbon Disclosure Project’s (CDP) A List of performance leaders. We also achieved a position on the 2014 CDP Supplier Climate Performance Leadership Index (SCPLI). This index showcases 121 supplier companies around the world
that are making the greatest progress towards mitigating climate change.

Our operational greenhouse gas footprint totalled 738,000 metric tonnes in 2014, a reduction of 18 percent from our 2010 baseline.

Using natural resources efficiently

While waste prevention is our goal, we also seek to dispose of our waste in the best way through treatment, recycling and the avoidance of landfill disposal when prevention is impractical. Since 2010, we have reduced our total waste by 24 percent and reduced hazardous waste by 36 percent. This is due principally to changing production patterns and a major investment at our manufacturing site in the UK to enable recycling and reuse of solvent wastes.

(We characterise our waste as either hazardous waste, such as chemical waste, or other waste, such as trash or rubbish, according to national legislation.)

All our manufacturing and R&D sites that use significant quantities of water or are located in a water-stressed area have water conservation plans in place. In 2014, our water use was 3.8 million cubic metres, a reduction of 17 percent from our 2010 baseline.

Driving environmental product stewardship

Environmental product stewardship encourages all those involved in the lifespan of a medicine to take responsibility to minimise the environmental impact of the product. Process Mass Intensity (PMI) is a resource-efficiency target developed collaboratively by the pharmaceutical industry and is a measure of the total quantity of all input raw material divided by the quantity of product made. It is important to strive for the lowest possible PMI for each project in development because this will reduce the amount of material used and waste generated for the lifetime of the product, which could be many years.

Our 2014 analysis of PMI, collated for pharmaceutical development projects, revealed that our continued efforts to improve the active pharmaceutical ingredient processes has led to a 22 percent reduction in PMI against the agreed baseline.

Improving our understanding of pharmaceuticals in the environment

To ensure our manufacturing discharges are safe, we developed the concept of Environmental Reference Concentrations (ERCs) and Maximum Tolerable Concentrations (MTCs), which are standard levels and should not be exceeded in the aquatic environment receiving our effluents. To date, we have established ERCs and MTCs for 42 of our active pharmaceutical ingredients (APIs).

All our worldwide manufacturing sites meet our ERC criteria and we have a rolling programme to confirm ongoing compliance. In 2014, we completed 72 ERC assessments with our suppliers. We run an annual training event explaining our approach and methodology to our suppliers. We also work with national and local authorities to raise public awareness and provide guidance on the safe disposal of medicines.
 

Implementing sustainable construction methods

In 2016, our UK-based global R&D centre and corporate headquarters will relocate to a purpose-built facility on the Cambridge Biomedical Campus. The 2,000-person site will house the majority of the staff currently located in three existing UK sites.

AstraZeneca took the decision early on in the project to work with our partners to deliver a sustainable design for the facility, capable of achieving Building Research Establishment Environmental Assessment Methodology (BREEAM) ‘Excellent’ ratings for sustainability performance. In order to achieve this, the facility must gain 70 percent of the available credits.

The R&D Centre has 73 percent of these credits confirmed with a further 12.7 percent being targeted, while the R&D Enabling Building has 74 percent of its credits confirmed with a further 16.7 percent of the score being targeted.

Many of the steps taken to reduce energy consumption on the site have been based on learning from our existing Mölndal R&D site in Sweden, which is a best-practice example from an energy use perspective. For example, the optimisation of natural light, a combined heat and power station and a rainwater recovery system reduce energy consumption and the environmental footprint of the facility. Per scientist, the Cambridge site will be twice as energy efficient as Mölndal.

Environmental risk data relating to our medicines

The tables below provide an overview of the environmental risk of AstraZeneca’s medicines. This information will be updated, if appropriate, as new data become available.

Cardiovascular

For information on the individual pharmaceutical click on the compound name in the table below.

Brand nameGeneric nameTherapy areaEnvironmental Risk
Tenormin, Tenormine, Prenormine, Atenol Atenolol (PDF 151kb) Cardiovascular Insignificant
Nif-Ten (atenolol - nifedipine) Atenolol (PDF 151kb) Cardiovascular Insignificant
Tenoretic (atenolol - chlorthalidone) Atenolol (PDF 151kb) Cardiovascular Insignificant
Atacand Candesartan cilexetil (PDF 237kb) Cardiovascular Insignificant
Atacand Plus (candesartan cilexetil – hydrochlorothiazide) Candesartan cilexetil (PDF 237kb) Cardiovascular Insignificant
Tenoretic (atenolol - chlorthalidone) Chlorthalidone (PDF 150kb) Cardiovascular *
Forxiga** Dapagliflozin (PDF 129kb) Cardiovascular Insignificant
Lexxel (enalapril maleate - felodipine) Enalapril Maleate (PDF 153kb) Cardiovascular *
Plendil, Modip, Splendil, Munobal, Flodil Felodipine (PDF 162kb) Cardiovascular Low
Unimax (felodipine - ramipril) Felodipine (PDF 162kb) Cardiovascular Low
Lexxel (enalapril maleate - felodipine) Felodipine (PDF 162kb) Cardiovascular Low
Logimax (felodipine-metoprolol) Felodipine (PDF 162kb) Cardiovascular Low
Zestoretic (lisinopril dihydrate - hydrochlorothiazide) Hydrochlorothiazide (PDF 152kb) Cardiovascular Insignificant
Atacand Plus (candesartan cilexetil – hydrochlorothiazide) Hydrochlorothiazide (PDF 152kb) Cardiovascular Insignificant
Imdur, Coleb-Duriles, Duronitrin, Monodur, Pertil Retard, Promocard 60 Durettes Isosorbide-5-mononitrate (PDF 140kb) Cardiovascular *
Zestoretic (lisinopril dihydrate - hydrochlorothiazide) Lisinopril Dihydrate (PDF 117kb) Cardiovascular Insignificant
Zestril Lisinopril Dihydrate (PDF 117kb) Cardiovascular Insignificant
Logimax (felodipine-metoprolol) Metoprolol Succinate (PDF 147kb) Cardiovascular Low
Seloken ZOK, Toprol-XL, Betaloc ZOK, Betaloc. Seloken Metoprolol Succinate (PDF 147kb) Cardiovascular Low
Nif - Ten (atenolol - nifedipine) Nifedipine (PDF 150kb) Cardiovascular *
Inderal, Inderal LA, Avlocardyl, Avlocardyl retard, Dociton, Inderalici, Sumial  Propranolol Hydrochloride (PDF 247kb) Cardiovascular Low
Unimax (felodipine - ramipril) Ramipril (PDF 142kb) Cardiovascular Insignificant
Crestor Rosuvastatin Calcium (PDF 249kb) Cardiovascular Insignificant
Onglyza** Saxagliptin (PDF 139kb) Cardiovascular Insignificant
Brilinta, Brilique Ticagrelor (PDF 241kb) Cardiovascular Insignificant

*Limited data available. See pdf document.

**ONGLYZA™ and FORXIGA™ have been developed by an alliance between AstraZeneca and Bristol-Myers Squibb.

Click here (PDF 1096kb) to download all available environmental data and supporting information in the Cardiovascular therapy area.

 

Gastrointestinal

For information on the individual pharmaceutical click on the compound name in the table below.

Brand nameGeneric nameTherapy areaEnvironmental Risk
Entocort Budesonide (PDF 158kb) Gastrointestinal Insignificant
Nexium Esomeprazole and Omeprazole (PDF 136kb) Gastrointestinal Insignificant
Losec, Gastroloc, Mopral, Omepral, Prilosec Esomeprazole and Omeprazole (PDF 136kb) Gastrointestinal Insignificant
Click here (PDF 320kb) to download all available environmental data and supporting information in the Gastrointestinal therapy area.

 

Infection

For information on the individual pharmaceutical click on the compound name in the table below.

Brand nameGeneric nameTherapy areaEnvironmental Risk
Merrem/Meronem Meropenem (PDF 126kb) Infection Insignificant
Zinforo* Ceftaroline (PDF 108kb) Infection Insignificant
Click here (PDF 272kb) to download all available environmental data and supporting information in the Infection therapy area.

* Zinforo™ has been developed by an alliance between AstraZeneca and Forest.

Neuroscience

For information on the individual pharmaceutical click on the compound name in the table below.

Brand nameGeneric nameTherapy areaEnvironmental Risk
Marcaine/Sensorcaine Bupivacaine Hydrochloride (PDF 162kb) Neuroscience *
Xylocaine Lidocaine Hydrochloride Monohydrate (PDF 111kb) Neuroscience Insignificant
Carbocaine Mepivacaine Hydrochloride (PDF 143kb) Neuroscience *
Citanest Prilocaine Hydrochloride (PDF 167kb) Neuroscience Insignificant
Diprivan Propofol (PDF 241kb) Neuroscience Low
Seroquel Quetiapine Fumarate (PDF 141kb) Neuroscience Insignificant
Naropin Ropivacaine Hydrochloride Monohydrate (PDF 108kb) Neuroscience Insignificant
Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon Zolmitriptan (PDF 132kb) Neuroscience Insignificant

*Limited data available. See pdf document.

Click here (PDF 636kb) to download all available environmental data and supporting information in the Neuroscience therapy area.

 

Oncology

For information on the individual pharmaceutical click on the compound name in the table below.

Brand nameGeneric nameTherapy areaEnvironmental Risk
Arimidex Anastrozole (PDF 124kb) Oncology Insignificant

Casodex,
Cosudex

Bicalutamide (PDF 122kb) Oncology Insignificant
Faslodex Fulvestrant (PDF 137kb) Oncology Low
Iressa Gefitinib (PDF 150kb) Oncology Insignificant
Zoladex Goserelin (PDF 107kb) Oncology Insignificant

Nolvadex,
Istubal,
Valodex

Tamoxifen (PDF 197kb) Oncology Insignificant
Caprelsa Vandetanib (PDF 125kb) Oncology Insignificant
Click here (PDF 530kb) to download all available environmental data and supporting information in the Oncology therapy area.

 

Respiratory

For information on the individual pharmaceutical click on the compound name in the table below.

Brand nameGeneric nameTherapy areaEnvironmental Risk
Bambec, Oxeol Bambuterol Hydrochloride (PDF 93kb) Respiratory Insignificant
Pulmicort, Spirocort, Rhinocort Budesonide (PDF 158kb) Respiratory Insignificant
Symbicort (budesonide – formoterol) Budesonide (PDF 158kb) Respiratory insignificant
Oxis Formoterol Fumarate Dihydrate (PDF 157kb) Respiratory Insignificant
Symbicort Formoterol Fumarate Dihydrate (PDF 157kb) Respiratory insignificant
Symbicort (budesonide – formoterol) Formoterol Fumarate Dihydrate (PDF 157kb) Respiratory insignificant
Bricanyl Terbutaline Sulphate (PDF 109kb) Respiratory Insignificant
Accolate, Accoleit, Vanticon Zafirlukast (PDF 134kb) Respiratory Insignificant
Click here (PDF 423kb) to download all available environmental data and supporting information in the Respiratory therapy area.

 

Downloads

Environmental impact icon

Find out more about our approach and progress on reducing our environmental impact: